-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in B-Cell Non-Hodgkin Lymphoma Drug Details: Nivolumab (Opdivo, Opdyta)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Ependymoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Ependymoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Ependymoma Drug Details: Nivolumab (Opdivo, Opdyta) is a human IgG4...
-
Sector Analysis
Hepatitis C Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Hepatitis C Tests Market Report Overview The Hepatitis C tests market size was valued at $1.77 billion in 2023 and will register a negative CAGR of less than 1% during 2023-2033. Hepatitis C virus (HCV) is an RNA virus belonging to the Flaviviridae family that can cause chronic hepatitis and cirrhosis. Test kits for HCV detection are used to identify HCV carriers, who may remain asymptomatic for many years. Hepatitis C Tests Market Outlook 2023-2033 ($ Billion) Buy the Full...
-
Product Insights
Gallbladder Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Gall Bladder Cancer Clinical Trial Report Overview A total of 620 Gall Bladder Cancer clinical trials were conducted as of December 2023. The Gall Bladder Cancer clinical trial report provides a comprehensive understanding of the Gall Bladder Cancer clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions...
-
Sector Analysis
Hepatitis B Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Hepatitis B tests Market Report Overview The hepatitis B tests market size was valued at $1.75 billion in 2023. The hepatitis B tests market will grow at a CAGR of more than 2% from 2023 to 2033. Hepatitis B is a viral infection caused by the Hepatitis B virus (HBV). The virus attacks the liver and can cause acute and chronic disease, which might lead to liver failure, liver cancer or liver cirrhosis, kidney disease, and/or inflammation of blood vessels....
-
Sector Analysis
Czech Republic Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2028
Czech Republic Defense Market Report Overview As of 2023, the Czech Republic defense budget was worth $4.7 billion. The country’s defense budget is set to see high levels of growth, registering a CAGR of more than 9% between 2024 and 2028. Factors such as the significant changes in the defense and security posture of the Czech Republic as a result of Russia’s 2022 full-scale invasion of Ukraine and expansion of military capability are driving the Czech Republic's defense market growth....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Bladder Cancer Drug Details: Nivolumab (Opdivo, Opdyta) is a human IgG4 anti-PD-1 monoclonal...
-
Track & Monitor
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Platinum as active pharmaceutical ingredient segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Product Insights
Parasitology and Mycology Rapid Tests and POC Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies
Parasitology and Mycology Rapid Tests and POC Pipeline Market Report Overview Parasitology and mycology consist of rapid test kits. These are used for rapid diagnosis, with immediate results, through immunoassays for Plasmodium and Candida albicans. The Parasitology and Mycology Rapid Tests and POC pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EXS-4318 in Autoimmune Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EXS-4318 in Autoimmune Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EXS-4318 in Autoimmune DisordersDrug Details:EXS-4318 is under development for the treatment of unspecified...